Back to Journals » Journal of Blood Medicine » Volume 10

Real-world experience of ibrutinib therapy in relapsed chronic lymphocytic leukemia: results of a single-center retrospective analysis

Authors Nuttall E, Tung J, Trounce E, Johnston R, Chevassut T

Received 21 January 2019

Accepted for publication 13 May 2019

Published 9 July 2019 Volume 2019:10 Pages 199—208

DOI https://doi.org/10.2147/JBM.S202286

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Melinda Thomas

Peer reviewer comments 2

Editor who approved publication: Dr Martin Bluth


Elisabeth Nuttall,1,2 Joanna Tung,3 Ellie Trounce,3 Rosalynd Johnston,2 Timothy Chevassut2,3

1Nelson Hospital, Nelson and Marlborough District Health Board, Nelson, New Zealand; 2Department of Haematology, Royal Sussex County Hospital, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK; 3Brighton and Sussex Medical School, University of Sussex, Brighton, UK

Background: Ibrutinib is a Bruton’s tyrosine-kinase (BTK) inhibitor that is approved as a second-line treatment in chronic lymphocytic leukemia (CLL). While recent trials have demonstrated impressive results for ibrutinib, there remains a paucity of real-world data on its use in the clinical setting.
Methods: In this single-center study carried out at Brighton and Sussex University Hospitals, we retrospectively compared outcomes in 38 patients with relapsed CLL who received ibrutinib versus those who received conventional first- and second-line therapies.
Results: Our results demonstrate improved progression-free survival (PFS, p=0.022) with ibrutinib versus conventional second-line therapies and survival comparable to conventional first-line therapies. However, there was a high frequency (81.6%) of adverse events associated with ibrutinib therapy, including 2 cases of death secondary to sepsis and a further 7 cases of discontinuation of treatment due to adverse events. We also identify del13q14.3 as an adverse predictor of response to ibrutinib with respect to both overall survival (p=0.014) and PFS (p=0.008), suggesting that these patients may be better suited to receiving the BCL2 inhibitor venetoclax.
Conclusion: Whilst there is robust evidence for improved outcomes with ibrutinib, we find that survival in patients with del13q14.3 is reduced and that the rate of adverse events and discontinuation in clinical practice is higher than anticipated from clinical trials.

Keywords: CLL, chronic lymphocytic leukaemia, relapsed, real-world, ibrutinib, adverse events


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]